These innovative compounds represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://rajanlnmw708741.eedblog.com/39372875/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide